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Mutation and DNA Methylation Assayrecombination (HR)emediated DNA double-strand break
repair, whereas PARP1 plays a major role in base excision
repair.4,5 Targeting PARP in BRCA1/2-defective tumors re-
sults in failure of at least two DNA repair pathways with
detrimental effects on the tumor cell.4e6 Although PARP
inhibitors (PARPi) are currently approved for BRCA1-mutant
cancer, their therapeutic indication will likely extend to
cancers displaying a BRCAness phenotype.7 These tumors
display a defective HR DNA repair in the absence of BRCA1
or BRCA2 mutations.8 Furthermore, many clinical studies are
investigating the use of PARPi in a wider spectrum of tumors
(eg, prostate, breast, lung, and colon cancer).9,10
Defects in DNA repair mechanisms can be due to muta-
tions or hypermethylation within promoter regions and sub-
sequent down-regulation of the corresponding gene.4,11e14
As far as genetic alterations are concerned, clinical studies
investigating the effect of PARPi according to mutations in
selected DNA repair genes are already ongoing (eg, clinical
trials NCT03061188, NCT02286687, and NCT02987543).
However, to broaden the analyses, and thereby improving the
stratification of patients who will respond to PARPi, inte-
grative analysis of DNA methylation and mutations in the
same tumor sample is required. Such technologies covering
bothdepigenetics and geneticsdfor a set of genes are not
yet available. Considering the growing number of targeted
therapies and biomarkers predictive of therapy response,
cost-effective assays capable of assessing the mutational and
methylation status of multiple genes are needed.
In the clinical diagnostic setting, panel sequencing of single
to hundreds of genes is well established and a few gene panels
were already approved or cleared by the US Food and Drug
administration: the Oncomine Dx Target Test by Thermo
Fisher Scientific (Waltham, MA), analyzing 23 cancer-related
genes; the FoundationOne CDx by Foundation Medicine
(Cambridge, MA)15; and the MSK-Impact16 (Integrated Mu-
tation Profiling ofActionableCancer Targets) by theMemorial
Sloan-Kettering Cancer Center (New York, NY). The latter
two are based on a hybridization capture assay and encompass
324 or 468 genes, respectively. In contrast, US Food and
Drug administrationeapproved diagnostic tests based on
DNA methylation are rare. So far, only two DNA
methylationebased US Food and Drug administratione
approved diagnostic tests for cancer exist: SEPT9 traded as Epi
proColon by Epigenomics AG (Berlin, Germany)17,18 and
Cologuard by Exact Sciences Corp. (Madison, WI), which
probe multiple DNA methylation and genetic markers and a
test for occult blood in feces. In addition to these approved tests,
Epigenomics is developing a methylation-based test for lung
cancer onmethylation sites in the SHOX2 and PTGER4 genes,
which already received a Conformité Européeneein vitro
diagnostic (CE-IVD) mark in Europe. Several other clinically
relevant DNA methylation alterations existdsome of which
directly influence diagnostic and therapeutic decisions.11,12,19
Hypermethylation of the MLH1 promoter, for example, is
used to discriminate hereditary and sporadic colorectal cancers,
and methylation of the MGMT promoter indicates greaterThe Journal of Molecular Diagnostics - jmd.amjpathol.orgsensitivity to the alkylating agent temozolomide in glioblas-
toma multiforme.2,3 Moreover, a recent in silico analysis
identified 39 hypermethylated DNA damage repair genes in
human cancers, which may represent novel therapeutic targets
for DNA damage repair targeting therapies.20 Approved clin-
ical tests for these alterations do not exist, and methylation
analyses are rarely undertaken in the clinical setting. This is
partly due to the additional work required for investigating
single loci and, on the other side, due to the intense costs for
large-scale epigenetic analyses.21,22
Most techniques for the analysis of DNA methylation rely
on bisulfite conversion of unmethylated cytosines to uracil,
followed by high-throughput sequencing or single-locus
analysis.23 Whole genome approaches, such as whole
genome bisulfite sequencing, theoretically cover all 28
million CpGs present in the human genome and are far too
expensive for most studies. Medium throughput assays, such
as the Methyl-Seq approach by Agilent Technologies
(Waldbronn, Germany), the SeqCap Epi CpGiant Probes by
Roche Sequencing (Pleasanton, CA), or the TrueSeq Methyl
Capture EPIC kit by Illumina (San Diego, CA), cover large
genomic regions of 84 Mb and 3.7 million CpGs, 80.5 Mb
and 5.5 million CpGs, or 107 Mb and 3.3 million CpGs,
respectively. The latest version of methylation arrays, the
Infinium MethylationEPIC Bead Chip Kit (Illumina), in-
terrogates 850,000 CpGs across the genome. Single loci are
investigated by pyrosequencing technologies, which can
perform methylation analyses on a large set of samples, but
with only one position at a time. The establishment of these
technologies surpasses the capability of most clinical diag-
nostic laboratories.
To overcome the technical limitations of only detecting
genetic alterations, a protocol was developed, which
combines methylation detection and mutational analyses
of a panel of regions of interest by using a targeted
hybrid selection and sequencing strategy. These regions
cover 342 genes involved in DNA repair and investigated
their mutational and DNA methylation status. As a proof
of principle, nine ovarian cancer cell lines, sensitive or
resistant to olaparib, were investigated. In addition, four
PARPi-resistant cell line models were generated through a
growth selection experiment in which clinical conditions
of PARPi delivery were simulated. Finally, the applica-
bility of the technology was shown for small DNA input
amounts and for formalin-fixed, paraffin-embedded
(FFPE) samples.Materials and Methods
Ethics Approval and Written Consent
The study was approved by the ethics review board of the
University Clinic of Cologne, under the reference number
13-091, and a written informed consent was obtained from
the patient.199
Grimm et alCell Lines
The ovarian cancer cell lines A2780, CAOV3, ES2,
FUOV1, OVCAR8, OVCA420, PEO1, SKOV3, and
SNU251,24 as well as the cell lines with acquired resistance
(CAOV3-olaparib, CAOV3-talazoparib, OVCAR8-
olaparib, and OVCAR8-talazoparib) were grown in RPMI
1640 medium (number 21875; Thermo Fisher Scientific,
Waltham, MA) supplemented with 10% fetal bovine serum
at 37C and 5% CO2. SNU251 was supplemented with 10
mg/mL insulin (C-52310; PromoCell GmbH, Heidelberg,
Germany). Cell lines were short tandem repeats finger-
printed to confirm identity and regularly tested for Myco-
plasma contamination using the MycoAlert PLUS detection
kit (Lonza, Basel, Switzerland).
Cell lines with acquired resistance to a PARP inhibitor
were developed after 5 months of continuous exposure of
each parental cell line (CAOV3 or OVCAR8) to escalating
doses of the PARP inhibitor (olaparib or talazoparib). A
dose selection strategy was used for each cell line/drug
combination to determine a starting dose that causes
maximal cell kill, while allowing return to logarithmic cell
growth. Selected doses corresponded to IC80 values
(inhibitory concentration at which 80% of the cells die) of
the PARP inhibitor for that particular cell line, while
remaining within the range of therapeutic drug levels
observed in phase 1 pharmacokinetic data, to obtain clini-
cally relevant resistant cell line models. For talazoparib,
dose escalation beyond in vivo therapeutic levels was
required to achieve stable resistant models. Parent cells were
grown in parallel to the developing resistant cells. The
established resistant cell lines were frozen at e80C, then
grown in drug-free media on defrosting, with resistance
maintained on cytotoxicity assays assessed up to 15 weeks
after defrost.
Cell Viability Assays
For each cell line, 1000 cells per well were seeded in a 96-
well plate. After 24 hours, cells were treated with vehicle
(dimethyl sulfoxide) and olaparib (Cayman Chemical
Company, Ann Arbor, MI) at concentrations of 0.0, 0.30,
0.89, 2.67, 8.00, and 24.00 mmol/L (A2780, CAOV3, ES2,
OVCAR8, SKOV3, SNU251, and PEO1) or at 0, 0.135,
0.625, 2.5, 10, and 40 mmol/L (FUOV1 and OVCA420)
because for the latter a higher half maximal inhibitory
concentration (IC50) value was expected with regard to
previously published experiments.24,25 Growth was deter-
mined at 120 hours in triplicate by measurement of the ATP
present, which signals the presence of metabolically active
cells using the CellTiter-Glo Assay (Promega, Mannheim,
Germany), according to the manufacturer’s instructions. The
luminescence was measured using a Tecan plate reader
Infinite M1000PRO (Tecan, Maennendorf, Switzerland).
The IC50 was determined from the regression of a plot of the
logarithm of the concentration versus percentage inhibition200at the time point of 120 hours using GraphPad Prism 7
(GraphPad Software, La Jolla, CA).
DNA Isolation
DNA from cell lines was isolated using the Qiamp DNA
Mini kit (Qiagen, Hilden, Germany), according to the manu-
facturer’s recommendations. DNA from FFPE material was
isolated using the Qiamp DNA FFPE Tissue kit (Qiagen).
DNA concentration wasmeasured using the Qubit dsDNABR
fluorescence assay (Thermo Fisher Scientific) and aNanoDrop
Spectrophotometer (Thermo Fisher Scientific) with similar
results. DNA quality was assessed on a 1% agarose gel.
Capture Library
The custom design of the capture library was performed
with the SureSelect DNA Advanced Design Wizard (Agi-
lent Technologies, Waldbronn, Germany) on the GRCh37/
hg19 genome build using the bait-boosting option balanced,
which takes the GC content of the targeted regions into
account by increasing the number of baits for GC-rich re-
gions. The library consisted of 43,724 probes (7382 regions)
encompassing 2.770 Mbp (design ID: 3080341)
(Supplemental Table S1) with a recommended sequencing
output of 554.186 Mbp. The coding and promoter regions of
342 genes implicated in the DNA damage response were
included in the design (Supplemental Table S1). An inter-
section of the library regions with selected genomic features
was performed using the University of California, Santa
Cruz, Table Browser (https://genome.ucsc.edu).26
Methylation and Mutational Analysis
DNA was sheared to a size of 150 to 200 bp with a Bioruptor
NGS (Diagenode, Seraing, Belgium) at 4C for 6 10 cycles
of 30 seconds on/off using high settings. Samples were vortex
mixed and briefly centrifuged after every 10 cycles. DNA
fragmentation was assessed with a High Sensitivity D1000
ScreenTape on a 2200 TapeStation (Agilent Technologies).
Library was prepared using the SureSelectXT Methyl
reagent kit (number G9651A; Agilent Technologies) and
Agencourt AMPure XP beads (Beckman Coulter, Krefeld,
Germany), according to Agilent’s recommendations (Agi-
lent protocol: SureSelectXT Methyl-Seq Target Enrichment
System for Illumina Multiplexed Sequencing version D0;
July 2015; G7530-90002; Santa Clara, CA) following the
protocol for 3 mg input DNA. If 6 mg input DNA was used,
two individual libraries were prepared, each with 3 mg of
input DNA. The FFPE-DNA was repaired after shearing
using the NEBNext FFPE DNA repair mix (New England
Biolabs, Frankfurt am Main, Germany). Subsequently, li-
braries were prepared following the manufacturer’s protocol
for 1 mg input DNA.
Hybridization was performed using a custom-designed
SureSelectXT 0.5 to 2.9 Mb library (number 5190-4816;jmd.amjpathol.org - The Journal of Molecular Diagnostics
Mutation and DNA Methylation AssayELID: 3080341; Agilent Technologies) with the methyl-
sequencing hybridization and enrichment reagents for 16
hours at 65C, according to the manufacturer’s protocol
(Agilent protocol: SureSelectXT Methyl-Seq Target Enrich-
ment System for Illumina Multiplexed Sequencing version
D0; July 2015; number G7530-90002). After hybridization,
Dynabeads MyOne Streptavidin T1 (Thermo Fisher Scien-
tific) were added to the hybridization mixture to capture the
DNA/RNA-biotin hybrids and incubated according to the
manufacturer’s protocol. Subsequently, beads were washed.
In the second washing step, beads were resuspended in 200
mL wash buffer and divided in two aliquots of 100 mL each.
Each 100 mL aliquot was put on a magnetic separator, the
wash buffer was completely removed, and the DNA was
eluted. For the AllCapmeth, the beads were resuspended in
20 mL elution buffer and separated on a magnetic separator.
The resulting eluted DNA was directly bisulfite converted
using the EZ DNA Methylation Kit (Zymo Research,
Freiburg, Germany) for 16 hours at 50C, followed by a
purification and two rounds of PCR amplification. A first
round was performed with eight PCR cycles and a second
round was performed with six PCR cycles using the Sure-
SelectXT Methyl reagent kit.
For the target sequencing, the beads were resuspended in
30 mL H2O and the bead-water mix was used in the first
PCR amplification for eight cycles, followed by a second
amplification for six cycles using the Herculase II Fusion
DNA Polymerase (Agilent Technologies).
The amplified libraries were purified using Agencourt
AMPure XP beads (Beckman Coulter). Concentration was
determined using the Qubit dsDNA HS assay and a Qubit
fluorometer (Thermo Fisher Scientific). The size and quality
of the amplified libraries were tested using a High Sensi-
tivity D1000 ScreenTape on a 4200 TapeStation (Agilent
Technologies) as well as by quantification using the KAPA
Library Quantification kit (Roche Diagnostics Deutschland
GmbH, Mannheim, Germany) and the 7900HT Sequence
Detection System (Applied Biosystems, Thermo Fisher
Scientific), and sequencing was performed with an Illumina
HiSeq4000 sequencer (Illumina) and a 75-bp paired end
protocol. Venn diagrams were generated with Venny 2.1
[Oliveros, J.C. (2007-2015) Venny], an interactive tool for
comparing lists with Venn diagrams (http://bioinfogp.cnb.
csic.es/tools/venny/index.html, last accessed May 22, 2018).
Mutational Analysis
Paired-end sequencing was processed using the VARBANK
version 1 pipeline of the Cologne Center for Genomics. In
brief, reads were aligned to the human reference genome
(GrCh37/hg19) using BWA-aln version 0.6.2, followed by
duplicate marking (Picard version 1.64), base quality score
recalibration, and local insertion/deletion realignment [both
Genome Analysis Toolkit (GATK) version 1.6-11]. Muta-
tions were called using the GATK best practice filter and an
allele frequency of 10%. Information about alleleThe Journal of Molecular Diagnostics - jmd.amjpathol.orgfrequencies or ClinVar annotations was obtained via the
web interface of the Ensembl Variant Effect Predictor27
using the Ensembl GRCh37, release 92. Variants with an
allele frequency >0.01 in any population of the 1000 Ge-
nomes or the gnomAD Project or classified as benign or
likely benign by ClinVar28 were excluded from further
analysis. The annotation was performed with Ensembl 68.
Methylation Analysis
Bisulfite-Sequencing Pipeline
Paired-end data were mapped against GrCh37/hg19 using
bsmap v2.90 with default parameters, except the maximum
allowed mismatches parameter (-v 0.1).29 Samtools v1.4 was
used to generate, sort, and index bam files and additionally
generate mapping statistics, excluding secondary alignments
(-F 256).30 IntersectBed v2.20.131 was used to calculate the
percentage of reads that intersect with designed target re-
gions. In addition, exclusively on-target bam files were
generated for the post mapping script methratio.py included
in the bsmap v2.90 package to calculate base-wise and
context-wise (CpG, CHG, CHH) methylation values with
adapted parameters [-t 3 -u -p -z -g -x (CGjCHGjCHH)].30
The methylation values calculated by the methratio.py
script depict the ratios of reads with a methylated cytosine to
the total number of reads covering one specific cytosine.
Chromosomal positions in combination with coverage or
methylation ratios were extracted to generate bedGraph
formatted files to convert it afterward in BigWig format using
bedGraphToBigWig of the University of California, Santa
Cruz, utilities.32 BigWig files were then loaded in the inte-
grative genomics viewer v2.3.78 to visualize the results.33,34
Metilene v0.2-735 was applied in de novo mode to call dif-
ferential methylated regions between the following samples
or sample sets: FFPE tumors versus FFPE normal; cell lines
versus merged cell lines data of nine cell lines (A2780,
CAOV3, ES2, FUOV1, OVCAR8_6mg_rep1, OVCA420,
PEO1, SKOV3, and SNU251); OVCAR8_6mg_rep2, 3 mg, 1
mg against OVCAR8_6mg_rep1 and against merged cell line
data and resistant CAOV3/OVCAR8 versus their corre-
sponding parental cell line (CAOV3 or OVCAR8_6m
g_rep1). Metilene filtering was set to q < 0.05 and a
difference value of 0.3, except for the OVCAR8 compari-
sons, in which no difference value was applied. A cutoff of
0.3 was used because the interquartile range over all differ-
entially methylated regions (DMRs) of all samples with
q-value cutoff < 0.05 ranged between 0.19 and 0.15
(Supplemental Figure S1A). Because the hypermethylated
regions are overrepresented in comparison to the hypo-
methylated regions, the absolute cutoff was used from the
lower interquartile range: 0.15. Methylation values for a
single cytosine can range between 0 and 1, but as differential
methylation can be positive (hypermethylation) and negative
(hypomethylation), ranging between 1 and 1, the absolute
cutoff was doubled, resulting in an overall methylation dif-
ference cutoff for called DMRs of 0.3. At a q-value cutoff of201
Grimm et alq < 0.05, 3409 DMRs were detected without a difference
value cutoff; applying a difference value cutoff of 0.3, 536
DMRs were detected (Supplemental Figure S1B).
Visualization of base-wise methylation patterns of genes
of interest was generated with a custom R script.
The methylation data were compared with the 450K
methylation data from the Cancer Cell Line Encyclopedia
project25 (https://www.ncbi.nlm.nih.gov/geo; accession number
GSE68379), available under the accession numbers:
CAOV3/CAOV-3: GSM1669661; OVCAR8/OVCAR-8:
GSM1670320; A2780: GSM1669581; ES2/ES-2:
GSM1669769; PEO1: GSM1670347; FUOV1/FU-OV-1:
GSM1669796; and SKOV3/SK-OV-3: GSM1670455.
Data have been downloaded from the National Center
for Biotechnology Information Gene Expression Omnibus
repository and converted to b values in R with minfi
v1.24.0.36 Bland-Altman analyses were performed using
GraphPad Prism 7.
Data Availability
Sequencing data of the cell lines are available at the National
Center for Biotechnology Information (https://www.ncbi.nlm.
nih.gov/bioproject; BioProject ID: PRJNA474810).
Results
Establishment of the AllCap Library for the Detection
of DNA Methylation and Mutations in DNA Repair
Pathway Genes
To set up a protocol for the detection of DNAmethylation and
mutation in a single assay, a hybrid-selectionebased targeted
technique, followed by post-capture bisulfite conversion,37
was adapted. This technique is based on the hybridization of
the targetedDNA to a biotin-labeledRNAstrand and capturingAllCapA B 




















Figure 1 Experimental design. A: Experimental workflow illustrating the proce
genes assigned to different Kyoto Encyclopedia of Genes and Genomes pathways
axis. C: Percentage of the repair panel regions having any intersection with the ind
Cruz (UCSC), Table Browser function. BER, base excision repair; BRCA1, BRCA1 in
hypersensitive clusters detected by ENCODE (DnaseClusteredV3); FA, Fanconi anemi
repair; NER, nucleotide excision repair; NGS, next-generation sequencing; NHE
identified by the ENCODE project using chromatin immunoprecipitation followed
202the DNA-RNA hybrid by streptavidin. Sequencing libraries
were first prepared from the DNA, and target capturing was
performed. The captured DNAs were then divided into two
parts, and one part was subjected to bisulfite conversion for
methylation analysis and the other part to PCR amplification
for mutation detection. During PCR amplification, indexes
were included, such that both parts could be pooled and
sequenced together (Figure 1A). In the following, we refer to
the protocol as AllCap assay because all (mutations and
methylation) can be captured, with DNAmethylation analyses
denoted as AllCapmeth and mutation analyses as AllCapmut.
For the design of the capture library, exons as well as pro-
moter regions and CpG island sequences were covered with
probes. A total of 342 genes implicated in DNA repair were
selected by searching the Reactome,38 Kyoto Encyclopedia of
Genes and Genomes,39e41 and Repairtoire42 databases and the
Search Tool for the Retrieval of InteractingGenes (STRING)43
database for BRCA1 interaction partners (Figure 1B and
Supplemental Table S2). The designed library contains the
promoter and the exons of the selected genes and encompasses
2.8 Mb with 72.808 CpGs (Supplemental Table S3). Of the
targeted regions, 10% overlap with CpG islands, 42% with
transcription factor binding sites, 58% at DNase I hypersen-
sitive sites, and 63% with known genes (Figure 1C). Over all
samples, a median of 52% and 55% of on-target reads was
obtained for the AllCapmut and AllCapmeth approaches,
respectively, which is in the frame of routine target enrichment
experimentswith small library sizes.44,45 The capture of coding
and noncoding regions was similar (Supplemental Figure S2).
For the initial experiment, nine ovarian cancer cell lines
(A2780, SNU251, OVCAR8, CAOV3, SKOV3, ES2,
PEO1, FUOV1, and OVCA420) with known BRCA1/2
mutation and BRCA1 methylation status24 and varying
sensitivities to olaparib were used (Supplemental Figure S3









































dure of the AllCap protocol. B and C: Panel composition. B: The number of
or of the BRCA1 interaction partners denoted by STRING are given on the y
icated genomic features determined with the University of California, Santa
teraction partner as denoted by STRING; CGI, CpG island; DNase I, DNase I
a; genes, UCSC known genes (hg19); HR homologous repair; MMR, mismatch
J, nonhomologous end joining; TFBS, transcription factor binding sites
by sequencing in different cell lines (TfbsClusteredV3).
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Figure 2 Data validation, correlation to publicly available data. A: Coverage plot for the BRCA1 gene and visualization of the known homo-
zygous BRCA1 mutation (c.5445G>A, p.W1815*) in the SNU251 cell line. The mutated nucleotide is highlighted in red (T, because BRCA1 is a
reverse strand gene). Chromosomal positions refer to hg19. B: Visualization of the DNA methylation of the BRCA1 promoter region. Each circle
represents one CpG (top four rows) or one CHG (bottom four rows) as control, with yellow low and red high methylation values. OVCAR8 contains
high promoter methylation of BRCA1.24 C: Heatmap depicting Pearson’s correlation between methylation values of the AllCap assay (AllCapmeth) and
publicly available 450K methylation array data from the Cancer Cell Line Encyclopedia project (450K) calculated by GraphPad Prism 7. D: Examples
of XY scatter plots visualizing the 450K array methylation b values on the y axis and the AllCapmeth methylation ratio values on the x axis. For the
AllCapmeth data, a minimum coverage of 10 reads per CpG was required. A total of 6557 CpGs were measured by both assays. E: Comparison of the
methylation values of 450K and AllCapmeth. Depicted are the 450K b methylation values on the y axis compared with the deciles of the AllCapmeth
methylation values for OVCAR8 as an example. Given is the mean, the boxes represent the 25% to 75% range, and the whiskers represent the 10%
to 90% range. F: Examples of Bland-Altman difference plots depicting the difference of the methylation values (AllCapmeth subtracted by 450K) on
the y axis and the average of the AllCapmeth and the 450K methylation values on the x axis. Dotted lines depict the 95% CI (limits of agreement).
CDS, coding sequence; chr17, chromosome 17; u.d., undetermined; UTR, untranslated region.
Mutation and DNA Methylation Assay
The Journal of Molecular Diagnostics - jmd.amjpathol.org 203
Grimm et alhybridized, and divided into two halfs, and from one part a
bisulfite conversion was performed. For the amplification of
bisulfite, converted DNA reagents from Agilent Technolo-
gies, which were optimized for bisulfite converted material,
were used.
Both parts, the bisulfite-converted and the targeted one,
were PCR amplified. During the second PCR amplification,
indexes were added. Subsequently, libraries were pooled
and sequenced with approximately 20 million reads output,
corresponding to 1500 Mb, resulting in a mean coverage of
approximately 230 for each, the targeted and the
methylation sequencing (Supplemental Table S5). Of the
72,808 CpGs present in the bait library, 84 were not covered
by any sample in the methylation sequencing (Supplemental
Tables S3 and S6 and Supplemental Appendix S1). Because
in mammals the predominant site of methylation occurs at
CpG sites, and cytosines in a CHH or CHG context (where
H Z A,T, or C) remain mostly unmethylated, the bisulfite
conversion rate was calculated from the CHH or CHG sites
and a mean conversion rate of 99.2% was obtained for the
nine cell lines (Supplemental Table S5). With this protocol,
the reported homozygous BRCA1 c.5564G>A, p.W1815*
mutation was detected in the SNU251 cell line (Figure 2A
and Supplemental Table S747e49) and the hypermethylation
of the BRCA1 promoter was detected in the OVCAR8
cells24 (Figure 2B and Supplemental Table S8). The ob-
tained methylation values were then compared with the
450K data generated by the Cancer Cell Line Encyclopedia
project.25 For the analysis, 6557 CpG sites were assessed by
both assays and had a coverage of at least 10 reads in our
assay. Pearson’s correlation for corresponding cell lines
ranged between 0.925 and 0.953 (Figure 2C), and the X-Y
scatter plots revealed a linear distribution (Figure 2D and
Supplemental Figure S4A). However, in the low methyl-
ation range, the 450K array data report slightly higher
values compared with the AllCapmeth values, whereas in the
high methylation range, the 450K array data reported
slightly reduced methylation values. This is also seen when
comparing the 450K methylation values with the deciles of
the AllCapmeth methylation values (Figure 2E). This pe-
culiarity of the 450K array was already recognized in a
study comparing several methylation assays.23 To further
compare the two methods, Bland-Altman analyses were
performed (Figure 2F and Supplemental Figure S4B),
which is commonly used to measure the difference be-
tween two methods. Comparing AllCapmeth with the 450K
data using Bland-Altman revealed a median range for the
limit of agreement of 0.23 to 0.19 at a 95% CI and a
median bias of 0.01 over all seven comparisons. More-
over, the root mean square error for all seven array/All-
Capmeth comparisons ranged between 0.095 and 0.139,
indicating a good concordance of the two methods. These
results revealed that the simultaneous detection of muta-
tions and DNA methylation with one capture library is
feasible and generates biologically relevant data for
assessing PARPi sensitivity.204Mutations and Methylation Alterations in Ovarian Cell
Lines Discovered with the AllCap Assay
In total, mutations were detected in 107 genes and the number
of mutated genes per cell line ranged from 3 to 36 in the cell
lines CAOV3 and A2780, respectively (Figure 3 and
Supplemental Table S7). Both cell lines are sensitive to
olaparib.
The most commonly mutated gene was TP53, which was
observed in eight of the nine cell lines. The occurrence of
mutations present in the olaparib-sensitive, but not in the
resistant, cell lines was evaluated. Ataxia telangiectasia and
rad3-related protein (ATR) and ataxia telangiectasia mutated
(ATM) mutations were present in sensitive cell lines
(CAOV3, SKOV3, and OVCAR8), which is in line with
previously published work.50e54 One BRCA1 mutation
(c.5564G>A, p.W1815*) was detected in SNU251, which
in our analysis showed a medium sensitivity to olaparib with
an IC50 value of 9.9 mmol/L after 5 days of treatment.
However, this is probably due to a reduced doubling time of
the SNU251 cells, and after 2 weeks of treatment, an IC50 of
2 mmol/L was measured.24 In the more resistant PEO1 cell
line, a deleterious homozygous BRCA2 mutation
(c.4965C>G, p.Y1655*) and a back mutation that reverses
the acquired stop mutation [c.4964A>T, p.Y1655F, allele
frequency (AF) Z 0.35] as resistance mechanism were
observed, as described previously.24 Interestingly, mutations
were detected in EP300 solely in sensitive cell lines (A2780,
SKOV3, and OVCAR8). EP300 encodes the E1A binding
protein P300, which acetylates histones and PARP1,55 and
PARP1 is activated on acetylation.56 In addition, interaction
of CREB binding protein (CREBBP)/EP300 with PARP1
promotes NF-kB activation,57 and recently, olaparib was
shown to up-regulate death receptors by NF-kB activation.58
Moreover, PARP1 was described to recruit EP300 to a
subset of promoters.59
Thus, besides known mutations in BRCA1, these data
support a role of ATM and ATR mutations in mediating
olaparib sensitivity60 and point to EP300 as a potential
candidate for enhancing olaparib sensitivity.
DMRs were calculated by comparing the individual cell
lines to the average methylation value of all nine cell lines,
identifying 28 to 54 DMRs per cell line at a significance
threshold of q < 0.05 (Supplemental Table S9). BRCA1 and
MGMT promoter DNA methylation were detected in the
OVCAR8 cell line (Supplemental Table S8), which is sen-
sitive to olaparib, with an IC50 of 4.8 mmol/L in our analysis.
Reproducibility of the Protocol and Reduction of the
DNA Input Amount
Next, the reproducibility of the assaywas tested using different
DNA amounts. Therefore, replicates were performedwith 6, 3,
and 1 mg of input DNA from the ovary cancer cell line
OVCAR8, and approximately 20 million reads per sample
were generated. In comparison to conventional hybrid-capturejmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 3 Mutations and differential methylation in homologous recombination genes (A), base excision repair genes (B), and BRCA1 interaction partners
(C) detected in nine cell lines sorted according to their olaparib sensitivity (sensitive left, resistant right). Methylation alterations refer to observed alterations
in the gene and/or the promoter regions. Red depicts hypermethylation; yellow, hypomethylation; crosses, mutations. Hyper; hypermethylation; Hypo,
hypomethylation; SNP, single-nucleotide polymorphism alteration.
Mutation and DNA Methylation Assayassays used for the initial experiments, rather high DNA input
amounts were used to account for a low yield after bisulfite
conversion. For the targeted sequencing, a slight reduction in
unique reads was observed for 1 mg of input DNA (64% versus
71% to 80%) (Supplemental Table S5), indicating an increase
in duplicate reads. For the AllCapmeth, the fraction of mapped
reads and on-target reads was comparable between the
different DNA input amounts (56% to 59%) and the calculated
bisulfite conversion efficiency exceeded 99% for all four rep-
licates (Supplemental Table S5).
The on-target coverage of the four replicates for the tar-
geted sequencing and the AllCapmeth samples was evalu-
ated. A marginal decrease in the coverage of the AllCapmeth
samples was observed, which is most likely because of the
reduced complexity of the bisulfite-treated samples, whereas
the individual replicates did not show any obvious differ-
ence in target coverage (Figure 4A). Regarding mutation
detection (AllCapmut), in all four replicates, the identical
protein-altering mutations were detected with similar allele
frequencies, revealing reproducible mutation detection with
DNA input amounts of 1 to 6 mg (Figure 4B and
Supplemental Table S1047e49).The Journal of Molecular Diagnostics - jmd.amjpathol.orgSubsequently, the global correlation of the methylation
values was assessed by one-to-one comparisons of the
different replicates. The Pearson’s correlation coefficient
of the replicates exceeds 0.995, whereas the correlation to
an unrelated ovary cell line, A2780, was < 0.89, indi-
cating an increased overall concordance between the
replicates from 1 to 6 mg DNA input (Figure 4C). Next,
the variation was assessed in local methylation levels by
calculating the number of DMRs detected in one-to-one
comparisons (q < 0.05). No DMRs were detected when
comparing 6 with 3 mg, and one DMR was detected when
comparing 6 with 1 mg of input DNA at a low methyl-
ation difference of 0.13 (Figure 4D). These results indi-
cate reliable detection of methylation using 3 mg of input
DNA. For 1 mg of input DNA, more detailed analyses (eg,
with inclusion of absolute methylation values) are
needed.
To verify the reproducibility of DMR detection, each of
the four replicates was compared with the average methyl-
ation values generated from nine different cell lines
(q < 0.05) (Supplemental Table S8). Adjacent DMRs that
were <500 bp apart were merged. After merging, 31 to 35205
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Mutation and DNA Methylation AssayDMRs were obtained per replicate, of which 28 were
detected in all four replicates (Figure 4E). Finally, Bland-
Altman analyses were performed and a limit of agreement
between our replicates was found at 10 coverage between
0.08 and 0.08 (Figure 4F). With an increase in coverage,
the range of the mean limit of agreement decreases to 0.04
to 0.04 at 400 coverage (Figure 4G), indicating a good
reproducibility of the AllCap assay.Assessment of the Suitability of AllCap for FFPE
Material
To test whether archived FFPE material from clinical tissue
specimens can be used for the AllCap assay, two tumor and
one matched normal FFPE specimen from a T-cell lym-
phoma patient were used. The tumor contains a known so-
matic ATM c.6326G>A, p.W2109* mutation. For the two
tumor samples, 0.9 and 0.25 mg DNA were used, respec-
tively, and for the normal sample, 1.2 mg DNA was used.
For targeted sequencing, approximately 20  106 reads
were generated per sample and thereof approximately 50%
were uniquely mapped for the two samples with 0.9 and 1.2
mg of input DNA. When 0.25 mg of input DNA was used,
only 23% of reads were uniquely mapped, revealing a high
number of off-target reads or duplicate reads. Nevertheless,
analyzing the mutations, the known tumor-specific ATM
mutation p.W2109* was reliably detected in both tumor
specimens with similar allele frequencies and coverage
rates. Three additional tumor-specific nonsynonymous mu-
tations were detected in both tumor samples (Supplemental
Table S1147e49), indicating that reduced DNA input amount
still allows the correct identification of mutations.
A similar result was observedwith theAllCapmeth protocol,
in which 43% and 47% of on-target reads were obtained for
the two samples with>0.9 mg of input DNA and 28% for the
sample with 0.25 mg input DNA. The calculated bisulfite
conversion efficiency was 92.9% for the 0.25 mg DNA input
sample compared with 98% and 98.4% for the two other
FFPE samples (Supplemental Table S5). This result indicates
that a low DNA input amount results in a reduced bisulfite
conversion rate as well as in an increase of duplicate and off-
target reads. However, for a coverage of 74, the fraction ofFigure 4 Evaluation of the reproducibility and reduction of input amount for t
different input amounts. The fraction of baits (nucleotides) is given on the y axis,
the replicates of OVCAR8. Given are the detected allele frequencies of protein al
technical replicates and different input amounts and for comparison of an unrelate
amount sample was used and compared with the second 6-mg sample (top left pa
(bottom left panel). Only CpGs covered in all samples by10 reads were used for
the calculation. D: Differentially methylated regions (DMRs) detected in the repl
filtered for significance (q < 0.05). The number of detected DMRs is given. E: Inte
OVCAR8 replicates with the average methylation value of nine different cell line
difference plots depicting a high concordance of the replicates. The difference o
replicates is depicted on the x axis. Dotted lines depict the 95% CI (limits of agre
cutoff on the x axis, revealing a decrease in variability at higher coverages. Seq,
The Journal of Molecular Diagnostics - jmd.amjpathol.orgbaits covered by the three FFPE samples was comparable
between the different samples (Figure 5A).
Comparing the global DNAmethylation of tumor 1 (0.9 mg
input) and tumor 2 (0.25 mg input) with normal reveals Pear-
son’s correlation coefficients of 0.97 and 0.96, respectively,
and between the two tumors of 0.98, indicating a highdegree of
concordance between the three samples. A high concordance
of global methylation, even between tumor and normal, is
conceivable because the specimens were derived from the
same individual and, especially, because our targeted panel is
small and only focal DNA methylation alterations are
expected. However, regardless of the high correlation values,
the scatter plot reveals a diversification of the methylation
values in the tumor versus normal comparisons in contrast to
the comparisons between the tumors (Figure 5B).
The identification of focal methylation alterations
revealed 23 DMRs (17 hypermethylated and 6 hypo-
methylated) for tumor 1 versus normal and 31 DMRs (26
hypermethylated and 5 hypomethylated) for tumor 2 versus
normal, of which 16 DMRs in 15 genes were detected in
both tumor specimens (11 hypermethylated and 4 hypo-
methylated) (Supplemental Table S12). Examples display-
ing the EYA4 and MGMT promoter are shown in Figure 5C.
EYA4 encodes the eyes absent homolog 4, a transcriptional
coactivator and phosphatase and is frequently methylated in
tumors.61 MGMT encodes a O(6)-methylguanine-DNA
methyltransferase, which is responsible for the repair of
methylated O(6)guanine adducts. A hypermethylation of the
MGMT promoter can result in gene silencing and a failure to
repair the mutagenic O(6)guanine adducts. It is a favorable
prognostic marker for the response to radiation or chemo-
therapy (eg, temozolomide) in glioblastoma.12e14 In the
tumor 2 specimen, a DMR was called in the MGMT pro-
moter; however, this DMR did not reach the significance
level of q < 0.05, probably because of the lower bisulfite
conversion rate (92%) of this sample (Figure 5D and
Supplemental Tables S5 and S12).
Mutations and DNA Hypermethylation in Cell Lines
with Acquired Resistance
To identify resistance mechanisms of PARP inhibition, two
cell line pairs with acquired resistance to the PARPi olaparibhe AllCap assay. A: Normalized coverage plot of the technical replicates with
and the normalized coverage is given on the x axis. B: Mutation detection in
tering mutations. C: Pearson’s correlation of the methylation levels of the
d cell line (A2780; bottom right panel). As reference, one of the 6-mg input
nel), the 3-mg input sample (top right panel), and the 1-mg input sample
the correlation calculation. Methylation levels of 0 and 1 were excluded from
icates of OVCAR8 cells. Pairwise comparisons were calculated by metilene,
rsection of DMRs that were called by pairwise comparisons of the individual
s is depicted as a Venn diagram generated by Venny 2.1. F: Bland-Altman
f the two replicates is depicted on the y axis, and the average of the two
ement). G: Given is the range of agreement on the y axis and the coverage
sequencing.
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Grimm et alor talazoparib were analyzed (Supplemental Table S4 and
Figure 6). These cell lines were generated by continuous
growth of sensitive parental cell lines (CAOV3 or
OVCAR8) in the presence of either drug over 5 months.
As denoted earlier, parental CAOV3 cells carry homo-
zygous mutations in TP53 (c.406C<T, p.Q136*) and
USP45 (c.1196A>G, p.N399S), and it is the cell line with
the least mutations in our DNA repair gene panel. Inter-
estingly, the parental CAOV3 cells carry a mutation in ATR
(c.569A>T, p.Q190L) with an allele frequency of 0.19.
This ATR mutation was not detected in the olaparib-resistant
cells, but is present in the talazoparib-resistant cells with an
allele frequency of 0.46 (Supplemental Table S1347e49).
Because an ATR mutation was not detected in the Cancer
Cell Line Encyclopedia data set25 and has a rather low allele
frequency of 0.19 in the parental CAOV3 cells, it is
conceivable that this mutation is an example of clonal
evolution in the CAOV3 cell line. Interestingly, inhibition
of ATR can overcome PARPi resistance51,52; therefore, an
initial ATR mutation with a small allelic fraction may be
deleted in the olaparib-treated cells. Moreover, PARPi
treatment increased phosphorylated ATR and a combination
treatment of PARP and ATR inhibitors synergistically
decreased survival in a cell line model.50 However, this
mutation was stable in the talazoparib-resistant cells, indi-
cating alternative mechanisms of PARPi resistance in this
cell line.
In regard to the DMRs in CAOV3 cells, talazoparib- and
olaparib-resistant cell lines share two hypermethylated sites,
RUVBL1 and BHLHE40, and one hypomethylation site in
NEDD4L. The hypermethylation in RUVBL1 occurs in a
CpG island in the last intron of a transcript variant of
RUVBL1, at the site of the RUVBL1-AS transcript, sug-
gesting a deregulation of RUVBL1 expression. The hyper-
methylation in BHLHE40 covers a CpG island present in the
coding region of the final exon. It is also observed in the
resistant cell lines FUOV1 and OVCA420, which points to a
potential association with olaparib resistance (Figure 6 and
Supplemental Table S8). However, a slight increase in
methylation in A2780 cells compared with the other cell
lines was also found, but it was below the level of
significance.
In contrast to the CAOV3 cell lines, significant DMRs
were not observed between the parental OVCAR8 and the
olaparib-resistant cell line. In the talazoparib-resistant cell
line, a promoter hypermethylation of the long transcript
variant of ERCC6 was observed (Supplemental Table S8).
ERCC6 encodes the excision repair cross-complemention
group 6, a chromatin remodeling factor and is involved in
nucleotide excision repair. However, OVCAR8 cells ac-
quired mutations during the resistance process, which would
indicate that there are different resistance mechanisms in the
two cell lines. Olaparib- and talazoparib-resistant OVCAR8
cells both displayed mutations in KPNA2 (c.224A>C,
p.N75T), TUBG1 (c.1239G>A, p.M413I), and USP1
(c.2147_2165, p.E717Afs*1499), pointing to a potential208role of these genes in mediating resistance to PARP in-
hibitors (Supplemental Table S1447e49). Interestingly, the
KPNA2 mutation was already present at a low allelic frac-
tion in the parental cell line (data not shown). Furthermore,
a reduction was observed in the allelic fraction of an O-6-
methylguanine-DNA methyltransferase (MGMT) mutation
(c.698C>T, p.P233L) from a nearly homozygous state
(AFZ 0.88) in the parental cell line to a heterozygous state
in the talazoparib- and olaparib-resistant cell lines (AF Z
0.55 and 0.33, respectively). To clarify if the p.P233L
mutation influences PARPi sensitivity, additional functional
experiments are needed. High MGMT expression has been
linked to temozolomide resistance in cancer, and several
studies reported synergistic effects of temozolomide and
PARP inhibitors.62e64Discussion
Stratification of patients for their response to a given
chemotherapeutic treatment is important considering the
growing number of personalized drugs, which target specific
molecular aberrations. This enables the selection of patients,
who respond to a given treatment, whereas nonresponders
are not unnecessarily exposed to adverse effects and it saves
precious time for an effective cure. For determining a useful
stratification strategy for PARPi, enormous efforts are un-
dertaken to identify responders.65 Mutations in one allele of
BRCA1 or BRCA2 together with loss of the wild-type allele
diminishes HR DNA damage repair and renders high-grade
ovarian cancers sensitive to PARPi. In addition, recent
PARPi clinical studies determine, besides BRCA mutation
status, efficiency of the HR system as a predictor for therapy
response. For example, the homologous recombination
deficiency score (eg, NOVA trial for niraparib,
NCT01847274) or loss of heterozygosity scores (ARIEL3
trial for rucaparib, NCT01968213) are used. These assays
can identify HR-deficient tumors regardless of the under-
lying mechanisms. On one side, this is an enormous
advantage; on the other side, it has been shown that some
responders are still not identified. Some patients, who are
BRCA negative and have a low homologous recombination
deficiency score, benefit from a PARPi treatment. Thus, the
AllCap assay may close this gap and may function as an
additional system to identify responders. Furthermore, other
clinical trials are now analyzing the influence of additional
mutations on treatment response (eg, for the PARPi nir-
aparib, a trial starts), which will inquire the association of
approximately 40 DNA damage response genes to PARPi
response (NCT03207347). Besides mutations, epigenetic
alterations may result in a homologous repair deficiency.
However, a recent phase 2 clinical study did not observe a
correlation between BRCA1 methylation status and olaparib
response (NCT00753545).66 A second recent phase 2 study
analyzed BRCA1 and RAD51C methylation status and
































































































































































































































Figure 5 Application of formalin-fixed, paraffin-embedded (FFPE) material with the AllCap assay. A: Coverage plot of the three FFPE samples. The fraction
of baits (nucleotides) is given on the y axis, and the normalized coverage is depicted on the x axis. B: Scatter plots showing the Pearson’s correlation of the
methylation levels for each tumor compared with normal (top panels) and of the two tumors (bottom panel). r Value indicates the Pearson correlation
coefficient. Only CpGs covered in all samples by 10 reads were used for the correlation analysis. Methylation levels of 0 and 1 were excluded from the
calculation of the correlation. C: Example of two hypermethylated promoter regions, EYA4 and MGMT, in the tumors. Each CpG and CHG is depicted as a circle,
and the methylation level is color coded. D: Differentially methylated regions (DMRs) and mutations detected in the tumor versus normal comparisons. DMRs
were calculated by metilene and filtered for significance (q < 0.05). Mutations were calculated by Varbank. Protein altering mutations are displayed.
Hypermethylation is depicted in red, and hypomethylation is depicted in yellow. Crosses denote mutations in the corresponding gene. CDS, coding sequence;
Seq, sequencing; u.d., undetermined; UTR, untranslated region.
Mutation and DNA Methylation Assayfor rucaparib response compared with mutational analysis of
HR genes in BRCA1 wild-type tumors (NCT01891344).67
Both studies used a single-locus PCR-based approach for
testing the methylation level. Having a test on hand like the
protocol presented herein will facilitate the analysis of manyThe Journal of Molecular Diagnostics - jmd.amjpathol.orgloci in parallel and help to elucidate the role of DNA
methylation in drug response.
To simplify the analysis of DNA methylation in clinical
research, the AllCap protocol that allows the parallel anal-















































































































Figure 6 Overview over differentially methylated regions (DMRs) and
mutations detected in nine ovary cancer cell lines and four resistant CAOV3
and OVCAR8 cell lines. Shown are genes with DMRs or mutations emerging
in the resistant CAOV3 or OVCAR8 cell lines. DMRs were calculated by
metilene and filtered for significance (q < 0.05). DMRs for the left nine cell
lines were calculated in relation to an artificial background over all cell
lines, and DMRs for the PARPi resistant cell lines were calculated in relation
to their parental sensitive cell line. Mutations were calculated by Varbank,
and protein altering mutations are displayed. Hypermethylation is depicted
in red, and hypomethylation is depicted in yellow. Crosses denote muta-
tions in the corresponding gene. Cell lines are sorted from sensitive (left
A2780) to resistant (right OVCA420). SNP, single-nucleotide polymorphism.
Grimm et aldeveloped. Because a single capture library is used for both,
the mutation, and the methylation analysis, the costs for the
library preparation kit and the capture library are cut by half.
Moreover, hands-on-work time is considerably reduced
because most protocol steps take place in parallel.
The protocol was applied on 6, 3, and 1 mg of genomic
DNA, and good concordance of the obtained mutations and
methylation values was obtained, indicating the validity of
the approach.
Because for most clinical applications, 3 mg of input
DNA might be too high, the input amount was reduced.
Even with 250 ng DNA input, known mutations were reli-
ably detected and correlation of the methylation values be-
tween 1 and the 250 ng input was >0.98. However, an
increased rate of duplicate reads was received, which has
also been described for methyl-sequencing approaches
alone with 250 ng, albeit with an increased number of PCR
cycles (Agilent application note: Agilent SureSelectXT
Methyl-Seq Applications with Low-Input DNA and Smaller
Capture Libraries; 5991-7838EN; Santa Clara CA). In
addition, because of a diminished bisulfite conversion rate,
DNA input amounts <250 ng require further improvements
of the protocol. Because a considerable amount of DNA
input was lost during the library generation (Supplemental
Table S5), additional improvements of the library210preparation bear potential to further decrease the amount of
DNA input.
Within clinical studies, tissue specimens are routinely
used from large tissue banks where samples are stored as
FFPE material. Pioneering targeted resequencing studies
using FFPE material for next-generation mutational and
methylation sequencing already opened an important
resource for clinical studies.44,68e70 Therefore, the AllCap
protocol was tested on FFPE material in a proof-of-principle
study and sound results were observed. However, in tumor
tissue, an uncertain amount of tumor cells and nonneoplastic
cells was found, which can make the identification of so-
matic variants and differential methylation events difficult.
Thus, to access the complete performance characteristics of
the assay for FFPE material, additional experiments are
required. This is in particular also true to access the
analytical sensitivity (limit of detection) of the assay.
PARPi resistance is mediated by several genetic lesions.
For example, loss of SLFN11 predicts PARPi resistance in
small-cell lung cancer62 and high SLFN11 expression cor-
responds to sensitivity of combinations of PARPi with
temozolomide in Ewing sarcoma.71 Loss of Trp53bp1/
Tp53bp1 causes PARPi resistance in a Brca1-mutated breast
cancer mouse model.72 Interestingly, mutations were
detected in the corresponding human ortholog, TP53BP1, in
the sensitive SKOV3 cell line (c.1474G>A, p.V429I,
AF Z 0.74; and c.3573C>A, p.D1191E, AF Z 0.16). An
increased expression of the phosphoglycolate phosphatase
drug efflux transporters, Abcb1a and Abcb1b, mediates
resistance to olaparib but not to PARP inhibitors that are not
a substrate of phosphoglycolate phosphatase.73 Such alter-
ations might be due to differential methylations and can thus
be detected by the AllCap assay. Moreover, phosphorylation
of the mammalian target of rapamycin target ribosomal
protein S6 confers PARPi resistance in a Brca1-deficient
mouse model.65 Also, PARPi sensitivity has been associated
with mutations in several DNA repair genes [eg, ATM, ATR,
CHEK1, CHEK2, SEM1 (alias DSS1), FANCA, FANCC,
FANCD2, NBN (alias NBS1), RAD51, ATRX (alias RAD54),
or RPA1].5,6,8,74 In the pilot experiment, ATR, ATM, and
EP300 mutations were detected solely in the sensitive cell
lines, in line with previously published results.4,6,8,55,74
Hypermethylation was also found within the basic helix-
loop-helix family member E40 (BHLHE40; alias STRA13,
DEC1, or SHARP2) and the CCNA1 genes in resistant cell
lines. Interestingly, a knockdown of BHLEH40 decreased
the amount of cleaved PARP after treatment with paclitaxel,
suggesting that a hypermethylation of the last exon of
BHLHE40 might have an effect on BHLHE40 transcription
and on PARP1 level.75e77 Because we detected a hyper-
methylation of the BHLHE40 also in olaparib-resistant cell
lines FUOV1 and OVCA420, this might be useful as a
biomarker for therapy resistance. However, the potential
resistance markers identified herein require an independent
validation in a larger cohort and experimental validation.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Mutation and DNA Methylation AssayTaken together, the presented approach will be in
particular useful for diagnostic/therapeutic purposes, as has
been shown herein using prediction of PARPi sensitivity as
an example. Possible implementations of the AllCap assay
might be, from a scientific point of view, to identify causes
of high homologous recombination deficiency scores and,
from a clinical point of view, to identify patients with
BRCA-negative and low HR deficiency scores, but who
respond to PARPi. A combination of both assay systems
may identify more responders. However, additional clinical
studies are required to truly develop a clinical assay based
on the protocol provided herein. Similarly, for the molecular
genetic and epigenetic analyses of imprinting disorders, like
Prader-Willi/Angelman syndrome or Beckwith-Wiedemann
syndrome, the parallel assessment of mutations or poly-
morphisms for the discrimination of alleles and differential
methylations will be useful. However, other applications
include integrated epigenome- and genome-wide association
studies to decipher complex diseases and the influence of
the genotype on the epigenetic variation.78,79 Thus, this will
open new routes in routine clinical diagnostics, but also
basic scientific research.Acknowledgments
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